TFS CAPITAL LLC - PROGENICS PHARMACEUTICALS IN ownership

PROGENICS PHARMACEUTICALS IN's ticker is PGNX and the CUSIP is 743187106. A total of 120 filers reported holding PROGENICS PHARMACEUTICALS IN in Q1 2016. The put-call ratio across all filers is 2.18 and the average weighting 0.1%.

Quarter-by-quarter ownership
TFS CAPITAL LLC ownership history of PROGENICS PHARMACEUTICALS IN
ValueSharesWeighting
Q2 2017$531,000
-64.8%
78,134
-55.2%
0.21%
-48.4%
Q4 2016$1,507,000
+488.7%
174,408
+187.9%
0.40%
+757.4%
Q2 2016$256,000
-56.8%
60,575
-55.4%
0.05%
-44.7%
Q1 2016$592,000
-75.7%
135,803
-65.9%
0.08%
-67.7%
Q4 2015$2,441,000
+572.5%
398,283
+527.1%
0.26%
+651.4%
Q3 2015$363,000
-83.9%
63,509
-79.0%
0.04%
-84.2%
Q2 2015$2,258,000
-45.3%
302,741
-56.1%
0.22%
-45.3%
Q1 2015$4,125,000
+17.7%
689,759
+48.7%
0.40%
+21.0%
Q4 2014$3,506,000
+2576.3%
463,740
+1740.1%
0.33%
+2936.4%
Q3 2014$131,000
-65.9%
25,202
-71.7%
0.01%
-63.3%
Q2 2014$384,000
-37.0%
88,983
-40.4%
0.03%
-25.0%
Q1 2014$610,000
-26.1%
149,185
-3.6%
0.04%
+2.6%
Q4 2013$825,000
-15.2%
154,734
-20.2%
0.04%
-11.4%
Q3 2013$973,000
+101.9%
193,901
+79.4%
0.04%
+120.0%
Q2 2013$482,000108,0650.02%
Other shareholders
PROGENICS PHARMACEUTICALS IN shareholders Q1 2016
NameSharesValueWeighting ↓
Broadfin Capital, LLC 1,583,925$8,007,0001.48%
Phocas Financial Corp. 1,022,708$5,169,0000.55%
RICE HALL JAMES & ASSOCIATES, LLC 1,776,490$8,980,0000.32%
FARALLON CAPITAL MANAGEMENT LLC 7,350,000$37,154,0000.28%
NEXPOINT ASSET MANAGEMENT, L.P. 716,880$3,624,0000.23%
J. Goldman & Co LP 499,698$2,526,0000.19%
PINNACLE ASSOCIATES LTD 1,257,098$6,355,0000.15%
CARILLON TOWER ADVISERS, INC. 3,948,024$19,957,0000.14%
EAGLE ASSET MANAGEMENT INC 4,504,094$22,768,0000.12%
Worth Venture Partners, LLC 32,956$167,0000.10%
View complete list of PROGENICS PHARMACEUTICALS IN shareholders